Theranostic biomarkers in hypertrophic cardiomyopathy insights in a long road ahead

The study of biomarkers and their related signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. However, in hypertrophic cardiomyopathy (HCM), which is the most common hereditary cardiac disease, there are many potential biomarkers described, but thei...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioscience Vol. 22; no. 10; pp. 1724 - 1749
Main Author Lazzeroni, Davide
Format Journal Article
LanguageEnglish
Published Singapore 01.06.2017
Subjects
Biomarkers - metabolism
Cardiomyopathy, Hypertrophic - diagnosis
Cardiomyopathy, Hypertrophic - genetics
Cardiomyopathy, Hypertrophic - metabolism
DNA Methylation
Epigenesis, Genetic
Histones - metabolism
Humans
MicroRNAs - genetics
Mutation
Sensitivity and Specificity
Theranostic Nanomedicine - methods
Online AccessGet full text

Cover

More Information
Summary:The study of biomarkers and their related signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. However, in hypertrophic cardiomyopathy (HCM), which is the most common hereditary cardiac disease, there are many potential biomarkers described, but their specificity and applicability for HCM remains an open field. The aim of the present review is to provide an overview of molecules that could give some insight into the pathophysiologic mechanisms underlying HCM, especially to those with "theranostic" - a combination of diagnostics and therapy - potential. The clinical and pre-clinical state of the art and theranostic perspectives of this topic will be part of the current discussion. The better understanding of this subject would provide an algorithm, to optimize the integration of diagnosis, prognostics and therapeutics findings in HCM, leading to a tailored approach for this pathology.
ISSN:1093-9946
1093-4715
2768-6698
DOI:10.2741/4568